SG11201408746XA - Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides - Google Patents
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotidesInfo
- Publication number
- SG11201408746XA SG11201408746XA SG11201408746XA SG11201408746XA SG11201408746XA SG 11201408746X A SG11201408746X A SG 11201408746XA SG 11201408746X A SG11201408746X A SG 11201408746XA SG 11201408746X A SG11201408746X A SG 11201408746XA SG 11201408746X A SG11201408746X A SG 11201408746XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- prot
- aium
- pct
- immunogenic polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 9 January 2014 (09.01.2014) WIPOIPCT (10) International Publication Number WO 2014/006191 A1 (51) International Patent Classification: A61K39/155 (2006.01) C12N15/863 (2006.01) C12N15/861 (2006.01) C07K16/44 (2006.01) (21) International Application Number: PCT/EP2013/064286 (22) International Filing Date: 5 July 2013 (05.07.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2012/063196 5 July 2012 (05.07.2012) EP (71) Applicant: OKAIROS AG [CH/CH]; Elisabethenstr. 3, CH-4051 Basel (CH). (72) Inventors: NICOSIA, Alfredo; Via Parco Carelli 70, I- 80123 Naples (IT). CORTESE, Ricardo; Rheinsprung 5, CH-4015 Basel (CH). VITELLI, Alessandra; Via GB Niccolini 10,1-00152 Rome (IT). (74) Agent: ZWICKER, Jork; ZSP Patentanwalte, Partner - schaftsgesellschaft, Radlkoferstrasse 2, 81373 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: NOVEL PRIME-BOOSTING REGIMENS INVOLVING IMMUNOGENIC POLYPEPTIDES ENCODED BY POLY NUCLEOTIDES Fig. 1 10000000 1000000 100000 10000 o\ T-H o o F prot + Aium Fprot + Alum/F Panad3 IN/ F Panad3IM/F prot + Alum prot + Aium prot + Aium © (57) Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition com - ^ prising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration Q of a vaccine composition and enhance the immune response against the immunogenic polypeptide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/063196 WO2014005643A1 (en) | 2012-07-05 | 2012-07-05 | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
PCT/EP2013/064286 WO2014006191A1 (en) | 2012-07-05 | 2013-07-05 | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408746XA true SG11201408746XA (en) | 2015-01-29 |
Family
ID=48746554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408746XA SG11201408746XA (en) | 2012-07-05 | 2013-07-05 | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
Country Status (19)
Country | Link |
---|---|
US (3) | US20150209420A1 (en) |
JP (1) | JP6244358B2 (en) |
KR (1) | KR20150038010A (en) |
CN (1) | CN104780937A (en) |
AU (1) | AU2013285398A1 (en) |
BR (1) | BR112014033077A2 (en) |
CA (1) | CA2878367A1 (en) |
DK (1) | DK2869841T3 (en) |
EA (1) | EA201492230A1 (en) |
ES (1) | ES2895070T3 (en) |
HU (1) | HUE056675T2 (en) |
IL (1) | IL236414A0 (en) |
IN (1) | IN2014KN03063A (en) |
LT (1) | LT2869841T (en) |
MX (1) | MX365391B (en) |
PT (1) | PT2869841T (en) |
SG (1) | SG11201408746XA (en) |
WO (2) | WO2014005643A1 (en) |
ZA (1) | ZA201500102B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03442B (en) | 2013-04-25 | 2020-01-20 | Janssen Vaccines & Prevention Bv | Stabilized soluble prefusion rsv f polypeptides |
BR112016028816A8 (en) * | 2014-06-13 | 2021-07-20 | Glaxosmithkline Biologicals Sa | immunogenic combination, method of obtaining a specific immune response, use of an immunogenic combination, and, vaccination regimen for the prevention, reduction or treatment of respiratory syncytial virus infection |
EP3188754A1 (en) | 2014-09-03 | 2017-07-12 | Bavarian Nordic A/S | Methods and compositions for enhancing immune responses |
MY183072A (en) | 2014-09-03 | 2021-02-10 | Bavarian Nordic As | Methods and compositions for inducing protective immunity against filovirus infection |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
EP3294326B1 (en) | 2015-05-15 | 2021-04-21 | CureVac AG | Prime-boost regimens involving administration of at least one mrna construct |
IL288541B (en) | 2015-07-07 | 2022-08-01 | Janssen Vaccines Prevention B V | Vaccine against rsv |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
SG11201807912SA (en) | 2016-04-05 | 2018-10-30 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
MA52910A (en) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention Bv | PRE-FUSION PROTEIN F OF RSV SOLUBLE AND STABILIZED FOR USE IN THE PROPHYLAXIS OF RSV INFECTION |
CA3021341A1 (en) * | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
EP3464331B1 (en) | 2016-05-30 | 2020-10-28 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
EP3484507A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
US11192926B2 (en) | 2017-04-04 | 2021-12-07 | University Of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use |
US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
WO2018210871A1 (en) * | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
JP2020519663A (en) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
BR112020004143A2 (en) | 2017-09-15 | 2020-09-01 | Janssen Vaccines & Prevention B.V. | method for the safe induction of immunity against respiratory syncytial virus (rsv) |
US11643666B2 (en) * | 2017-10-25 | 2023-05-09 | Nouscom Ag | Eukaryotic cell line |
US20210154277A1 (en) * | 2017-11-07 | 2021-05-27 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
CA3095216A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
GB201910794D0 (en) * | 2019-07-29 | 2019-09-11 | Pirbright Inst | Vaccine |
CN112220921B (en) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | Combined vaccine for respiratory syncytial virus infection |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511845B1 (en) * | 1992-08-07 | 2003-01-28 | Alan R. Davis | Methods for producing an immune response against HIV-1 |
US6180398B1 (en) * | 1996-07-12 | 2001-01-30 | Virogeneitics Corporation | Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation |
GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
US7498024B2 (en) * | 2003-06-03 | 2009-03-03 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site |
EP2163260B1 (en) | 2004-01-23 | 2017-03-15 | MSD Italia S.r.l. | Chimpanzee adenovirus vaccine carriers |
JP2009529576A (en) * | 2006-03-10 | 2009-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Vaccines against viruses that cause persistent or latent infections |
US20070292922A1 (en) * | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
EP2104681A4 (en) * | 2007-01-05 | 2011-01-19 | Inseron Inc | A green fluorescent protein optimized for expression with self-cleaving polypeptides |
GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
US20090092635A1 (en) * | 2007-08-17 | 2009-04-09 | Wyeth | Heterologous prime-boost immunization regimen |
CL2007002710A1 (en) * | 2007-09-20 | 2008-01-04 | Univ Pontificia Catolica Chile | Immunogenic formulation that confers protection against infection or pathology caused by the respiratory syncytial virus (vrs) comprising an attenuated recombinant strain of mycobacterium; and use of the immunogenic formulation to prepare a vaccine to prevent, treat or attenuate infections of vrs. |
US7863425B2 (en) * | 2007-09-26 | 2011-01-04 | Cornell University | Compositions and methods for inhibiting Yersinia pestis infection |
GB0823497D0 (en) * | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
EP2550974A3 (en) * | 2009-05-18 | 2013-05-08 | Panacea Biotec Ltd. | Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA) |
US9095546B2 (en) * | 2009-07-20 | 2015-08-04 | National Health Research Institutes | Human respiratory syncytial virus (RSV) vaccine |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
WO2012085936A2 (en) * | 2010-12-20 | 2012-06-28 | Panacea Biotech Ltd | Recombinant respiratory syncytial virus plasmids and vaccines |
US9125870B2 (en) * | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
-
2012
- 2012-07-05 WO PCT/EP2012/063196 patent/WO2014005643A1/en active Application Filing
-
2013
- 2013-07-05 CN CN201380044981.3A patent/CN104780937A/en active Pending
- 2013-07-05 KR KR20157003211A patent/KR20150038010A/en not_active Application Discontinuation
- 2013-07-05 EA EA201492230A patent/EA201492230A1/en unknown
- 2013-07-05 DK DK13734111.1T patent/DK2869841T3/en active
- 2013-07-05 US US14/408,340 patent/US20150209420A1/en not_active Abandoned
- 2013-07-05 HU HUE13734111A patent/HUE056675T2/en unknown
- 2013-07-05 IN IN3063KON2014 patent/IN2014KN03063A/en unknown
- 2013-07-05 BR BR112014033077A patent/BR112014033077A2/en not_active Application Discontinuation
- 2013-07-05 JP JP2015519233A patent/JP6244358B2/en active Active
- 2013-07-05 ES ES13734111T patent/ES2895070T3/en active Active
- 2013-07-05 CA CA2878367A patent/CA2878367A1/en active Pending
- 2013-07-05 MX MX2014016119A patent/MX365391B/en active IP Right Grant
- 2013-07-05 AU AU2013285398A patent/AU2013285398A1/en not_active Abandoned
- 2013-07-05 WO PCT/EP2013/064286 patent/WO2014006191A1/en active Application Filing
- 2013-07-05 SG SG11201408746XA patent/SG11201408746XA/en unknown
- 2013-07-05 LT LTEPPCT/EP2013/064286T patent/LT2869841T/en unknown
- 2013-07-05 PT PT137341111T patent/PT2869841T/en unknown
-
2014
- 2014-12-23 IL IL236414A patent/IL236414A0/en unknown
-
2015
- 2015-01-07 ZA ZA2015/00102A patent/ZA201500102B/en unknown
-
2017
- 2017-11-01 US US15/800,245 patent/US20180256704A1/en not_active Abandoned
-
2023
- 2023-02-28 US US18/115,556 patent/US20240091338A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20150209420A1 (en) | 2015-07-30 |
AU2013285398A1 (en) | 2015-02-05 |
ZA201500102B (en) | 2017-09-27 |
JP6244358B2 (en) | 2017-12-06 |
HUE056675T2 (en) | 2022-02-28 |
WO2014006191A1 (en) | 2014-01-09 |
PT2869841T (en) | 2021-10-28 |
JP2015526403A (en) | 2015-09-10 |
EA201492230A1 (en) | 2015-06-30 |
MX2014016119A (en) | 2015-09-23 |
CA2878367A1 (en) | 2014-01-09 |
IL236414A0 (en) | 2015-02-26 |
US20240091338A1 (en) | 2024-03-21 |
CN104780937A (en) | 2015-07-15 |
LT2869841T (en) | 2021-11-25 |
BR112014033077A2 (en) | 2017-08-01 |
MX365391B (en) | 2019-05-31 |
US20180256704A1 (en) | 2018-09-13 |
KR20150038010A (en) | 2015-04-08 |
IN2014KN03063A (en) | 2015-05-08 |
DK2869841T3 (en) | 2021-10-25 |
ES2895070T3 (en) | 2022-02-17 |
WO2014005643A1 (en) | 2014-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408746XA (en) | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides | |
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
SG11201907744QA (en) | Replacement of cytotoxic preconditioning before cellular immunotherapy | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201805186VA (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201806538WA (en) | Engineered antigen presenting cells and uses thereof | |
SG11201806542PA (en) | Anti-mica antibodies | |
SG11201408054RA (en) | Pegylated oxm variants | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
SG11201808675VA (en) | Method and kit for the generation of dna libraries for massively parallel sequencing | |
SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
SG11201805494WA (en) | Mutated von willebrand factor |